BridgeBio Pharma Reports $110M Revenue Surge on Attruby Uptake

BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported strong fiscal Q2 2025 results, nearly doubling revenue to $110.6 million, driven by increased uptake of its drug Attruby, which showed a 59% relative risk reduction for serious events in variant ATTR-CM patients. The company ended the quarter with $756.9 million in cash and received a Buy rating from Cantor Fitzgerald. Comparatively, BioCryst Pharmaceuticals (NASDAQ:BCRX) is seen as more favorable than Aurinia Pharmaceuticals (NASDAQ:AUPH) by analysts, with a consensus target price suggesting a nearly 96% upside and stronger institutional ownership. BioAtla Inc (BCAB) has experienced volatile stock performance, with its price down over 80% from its 52-week high but showing a 6.64% increase in quarterly revenue year-over-year and higher recent trading volumes. In a comparison between BioAge Labs (NASDAQ:BIOA) and iBio (NYSE:IBIO), analysts favor iBio due to its stronger consensus rating and potential upside of over 535%, whereas BioAge Labs focuses on metabolic diseases and aging with a lead candidate showing promise in weight loss enhancement. These insights highlight differing investment prospects and clinical progress across multiple biopharmaceutical companies.